Sun Pharma announces approval to mkt generic Ethyol

20864 Investors following Sun Pharma. Share this News with them.

0

Like this story, share it with millions of investors on M3

Sun Pharma announces approval to mkt generic Ethyol

Sun Pharmaceutical announces USFDA approval to market generic Ethyol

Post your opinion here

 

0

Tweet

Share on Tumblr

RELATED NEWS Sun Pharma gets approval for generic Gemzar injection Buy Sun Pharma, tgt Rs 1450: HEM Securities Sun Pharma gets approval to mkt generic Demadex tablets Sun Pharma buys Taro Pharma shares from Brandes ALSO READ See latest News about Sun Pharma See previous management interviews See what other Experts & Brokerages are saying about Sun Pharma Sun Pharma BSE | NSE 25/05/12 Are Mutual Funds betting on Sun Pharma?

Sun Pharmaceutical Industries Ltd. announced that USFDA has granted approval for the Abbreviated New Drug Application (ANDA) to market a generic version of MedImmune's Ethyol®, amifostine for injection 500mg.

This generic amifostine for injection is therapeutically equivalent to MedImmune's Ethyol® amifostine for injection 500mg. Ethyol® has annual sales of approximately USD 80 million in the US.

Sun Pharma, being the first-to-file an ANDA for generic Ethyol® with a para IV certification, has a 180-day marketing exclusivity.

Ethyol® is covered under 3 patents - '471 (July 31, 2012), '731 (July 31, 2012) and '409 (Dec 8, 2017). This ANDA was filed with para IV certification against all the patents. Medimmune filed a suit in the District Court of Maryland and the case is under litigation.

Amifostine is used as an adjuvant in cancer treatment. Sun Pharma's amifostine for injection will be indicated for the reduction of kidney damage in patients who have advanced ovarian cancer and are being given repeat doses of cisplatin. 

Sourced From: Sun Pharmaceutical Industries Ltd